Avantor has expanded the ACE HPLC column portfolio with ACE BioPep, a new stationary phase specifically developed for high-resolution analysis of GLP-1 peptide therapeutics, including semaglutide, liraglutide and exenatide.
ACE BioPep has demonstrated separation of semaglutide and liraglutide from multiple thermal degradation products, addressing one of the key challenges in stability-indicating method development and impurity profiling.
For ChromSword users, this new selectivity opens additional possibilities during HPLC/UHPLC method development. Combining application-focused column chemistry with a systematic approach to exploring parameters such as gradient, temperature and mobile-phase composition can help chromatographers efficiently identify suitable conditions for challenging peptide separations.
ACE BioPep is available in 1.7, 2 and 5 µm particle sizes and multiple column dimensions, providing flexibility from rapid UHPLC screening to higher-resolution methods.
ACE BioPep + ChromSword: bringing new selectivity and smarter method development together for GLP-1 analysis.
Find app note here : ACE BioPep applications
Reach thousands of researchers worldwide. Fill in your details and our team will contact you shortly.
